Pretreatment waveform for irreversible electroporation

Information

  • Patent Grant
  • 12349964
  • Patent Number
    12,349,964
  • Date Filed
    Tuesday, September 28, 2021
    3 years ago
  • Date Issued
    Tuesday, July 8, 2025
    23 days ago
Abstract
An electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system including an ablation catheter and an electroporation generator. The ablation catheter including a handle, a shaft having a distal end, and catheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to electrical pulses. The electroporation generator operatively coupled to the catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to one or more catheter electrodes. Wherein the preconditioning pulse sequence includes preconditioning electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.
Description
TECHNICAL FIELD

The present disclosure relates to medical apparatus, systems, and methods for ablating tissue in a patient. More specifically, the present disclosure relates to medical apparatus, systems, and methods for ablation of tissue by electroporation.


BACKGROUND

Ablation procedures are used to treat many different conditions in patients. Ablation may be used to treat cardiac arrhythmias, benign tumors, cancerous tumors, and to control bleeding during surgery. Usually, ablation is accomplished through thermal ablation techniques including radio-frequency (RF) ablation and cryoablation. In RF ablation, a probe is inserted into the patient and radio frequency waves are transmitted through the probe to the surrounding tissue. The radio frequency waves generate heat, which destroys surrounding tissue and cauterizes blood vessels. In cryoablation, a hollow needle or cryoprobe is inserted into the patient and cold, thermally conductive fluid is circulated through the probe to freeze and kill the surrounding tissue. RF ablation and cryoablation techniques indiscriminately kill tissue through cell necrosis, which may damage or kill otherwise healthy tissue, such as tissue in the esophagus, phrenic nerve cells, and tissue in the coronary arteries.


Another ablation technique uses electroporation. In electroporation, or electro-permeabilization, an electric field is applied to cells to increase the permeability of the cell membrane. The electroporation may be reversible or irreversible, depending on the strength of the electric field. If the electroporation is reversible, the increased permeability of the cell membrane may be used to introduce chemicals, drugs, and/or deoxyribonucleic acid (DNA) into the cell, prior to the cell healing and recovering. If the electroporation is irreversible, the affected cells are killed through apoptosis.


Irreversible electroporation (IRE) may be used as a nonthermal ablation technique. In IRE, trains of short, high voltage pulses are used to generate electric fields that are strong enough to kill cells through apoptosis. In ablation of cardiac tissue, IRE may be a safe and effective alternative to the indiscriminate killing of thermal ablation techniques, such as RF ablation and cryoablation. IRE may be used to kill targeted tissue, such as myocardium tissue, by using an electric field strength and duration that kills the targeted tissue but does not permanently damage other cells or tissue, such as non-targeted myocardium tissue, red blood cells, vascular smooth muscle tissue, endothelium tissue, and nerve cells.


In some IRE procedures, the electroporation electrical pulses cause the unwanted side effect of skeletal muscle stimulation (SMS) and engagement. One way to reduce SMS, is to refine the IRE electrical pulses, such that the pulses are optimized to avoid SMS. Often this results in having a smaller ablation electric field and in creating smaller lesions. A way of delivering effective IRE energies while avoiding SMS is needed.


SUMMARY

In Example 1, an electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system including an ablation catheter and an electroporation generator. The ablation catheter including a handle, a shaft having a distal end, and catheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to electrical pulses. The electroporation generator operatively coupled to the catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to one or more catheter electrodes. Wherein the preconditioning pulse sequence includes preconditioning electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.


In Example 2, the electroporation ablation system of Example 1, comprising a surface patch electrode attached to the patient and configured to generate electric fields in the patient in response to the electrical pulses.


In Example 3, the electroporation ablation system of Example 2, wherein the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the surface patch electrode and sunk through the one or more catheter electrodes.


In Example 4, the electroporation ablation system of Example 2, wherein the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the one or more catheter electrodes and sunk through the surface patch electrode.


In Example 5, the electroporation ablation system of any of Examples 1-4, wherein the preconditioning pulse sequence includes bipolar electrical pulses that are sourced from at least one of the one or more catheter electrodes and sunk through at least another one of the one or more catheter electrodes.


In Example 6, the electroporation ablation system of any of Examples 1-5, wherein the preconditioning pulse sequence includes preconditioning pulses delivered at a selected frequency.


In Example 7, the electroporation ablation system of any of Examples 1-6, wherein the preconditioning pulse sequence includes preconditioning pulses ramped up in voltage from a lower voltage to a higher voltage over time.


In Example 8, the electroporation ablation system of any of Examples 1-7, wherein the preconditioning pulse sequence includes preconditioning pulses that include an exponentially decaying backside waveform that causes electrolysis near the targeted tissue.


In Example 9, the electroporation ablation system of any of Examples 1-8, wherein the preconditioning pulse sequence includes preconditioning pulses that are monophasic.


In Example 10, the electroporation ablation system of any of Examples 1-9, wherein the irreversible electroporation pulse sequence, including the preconditioning pulse sequence and the electroporation pulse sequence, is delivered to the patient in one or more of a refractory time of a heart of the patient, less than 330 milliseconds, and in a 100-250 millisecond window.


In Example 11, the electroporation ablation system of any of Examples 1-10, wherein the electroporation pulse sequence is delivered within the preconditioning pulse sequence.


In Example 12, the electroporation ablation system of any of Examples 1-11, wherein the electroporation pulse sequence includes bipolar electrical pulses delivered to one or more catheter electrode pairs of the catheter electrodes.


In Example 13, the electroporation ablation system of any of Examples 1-12, comprising an accelerometer configured to monitor skeletal muscle stimulation of the patient and wherein the electroporation ablation system is a closed loop system such that the electroporation generator is configured to deliver the preconditioning pulse sequence, detect tetany in the patient, and then deliver the electroporation pulse sequence, and wherein local impedance is measured to calculate pre-ablation and post-ablation values to evaluate lesion efficacy.


In Example 14, an electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system including an ablation catheter and an electroporation generator. The ablation catheter including a handle, a shaft having a distal end, and catheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to electrical pulses. The electroporation generator operatively coupled to multiple electrodes including one or more of a surface patch electrode and one or more catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to the multiple electrodes, wherein the electroporation generator delivers the electroporation pulse sequence during the preconditioning pulse sequence.


In Example 15, the electroporation ablation system of Example 14, wherein the preconditioning pulse sequence includes electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.


In Example 16, an electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system including an ablation catheter and an electroporation generator. The ablation catheter including a handle, a shaft having a distal end, and catheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to electrical pulses. The electroporation generator operatively coupled to the catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to one or more catheter electrodes, wherein the preconditioning pulse sequence includes preconditioning electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.


In Example 17, the electroporation ablation system of Example 16, comprising a surface patch electrode attached to the patient and configured to generate electric fields in the patient in response to the electrical pulses.


In Example 18, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the surface patch electrode and sunk through the one or more catheter electrodes.


In Example 19, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the one or more catheter electrodes and sunk through the surface patch electrode.


In Example 20, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes bipolar electrical pulses that are sourced from at least one of the one or more catheter electrodes and sunk through at least another one of the one or more catheter electrodes.


In Example 21, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes preconditioning pulses delivered at a selected frequency.


In Example 22, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes preconditioning pulses ramped up in voltage from a lower voltage to a higher voltage over time.


In Example 23, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes preconditioning pulses that include an exponentially decaying backside waveform that causes electrolysis near the targeted tissue.


In Example 24, the electroporation ablation system of Example 16, wherein the preconditioning pulse sequence includes preconditioning pulses that are monophasic.


In Example 25, the electroporation ablation system of Example 16, wherein the irreversible electroporation pulse sequence, including the preconditioning pulse sequence and the electroporation pulse sequence, is delivered to the patient in one or more of a refractory time of a heart of the patient, less than 330 milliseconds, and in a 100-250 millisecond window.


In Example 26, the electroporation ablation system of Example 16, wherein the electroporation pulse sequence is delivered within the preconditioning pulse sequence.


In Example 27, the electroporation ablation system of Example 16, wherein the electroporation pulse sequence includes bipolar electrical pulses delivered to one or more catheter electrode pairs of the catheter electrodes.


In Example 28, the electroporation ablation system of Example 16, comprising an accelerometer configured to monitor skeletal muscle stimulation of the patient and wherein the electroporation ablation system is a closed loop system such that the electroporation generator is configured to deliver the preconditioning pulse sequence, detect tetany in the patient, and then deliver the electroporation pulse sequence, and wherein local impedance is measured to calculate pre-ablation and post-ablation values to evaluate lesion efficacy.


In Example 29, an electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system including an ablation catheter and an electroporation generator. The ablation catheter including a handle, a shaft having a distal end, and catheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to electrical pulses. The electroporation generator operatively coupled to multiple electrodes including one or more of a surface patch electrode and one or more catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to the multiple electrodes, wherein the electroporation generator delivers the electroporation pulse sequence during the preconditioning pulse sequence.


In Example 30, the electroporation ablation system of Example 29, wherein the preconditioning pulse sequence includes preconditioning electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.


In Example 31, the electroporation ablation system of Example 29, wherein the electroporation pulse sequence includes bipolar electrical pulses delivered to selected pairs of the catheter electrodes.


In Example 32, a method of ablating targeted tissue in a patient by irreversible electroporation. The method comprising delivering an irreversible electroporation pulse sequence including delivering a preconditioning pulse sequence between multiple electrodes including one or more of a surface patch electrode and one or more catheter electrodes on a catheter to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient, and delivering an electroporation pulse sequence to the multiple electrodes to cause irreversible electroporation ablation of the targeted tissue.


In Example 33, the method of Example 32, wherein delivering a preconditioning pulse sequence includes delivering electrical pulses that ramp up in voltage from a lower voltage to a higher voltage over time and wherein one or more of the electrical pulses include an exponentially decaying backside waveform.


In Example 34, the method of Example 32, wherein the electroporation pulse sequence is delivered during the preconditioning pulse sequence.


In Example 35, the method of Example 32, comprising monitoring an accelerometer on the patient and in a closed loop system, delivering the preconditioning pulse sequence to achieve tetany in the patient, detecting tetany in the patient via the accelerometer, and delivering the electroporation pulse sequence after tetany has been achieved.


While multiple embodiments are disclosed, still other embodiments of the present disclosure will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the disclosure. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a diagram illustrating an exemplary clinical setting for treating a patient and for treating a heart of the patient, using an electrophysiology system, in accordance with embodiments of the subject matter of the disclosure.



FIG. 2A is a diagram illustrating a distal end of a shaft included in a catheter and interactions between electrode pairs, in accordance with embodiments of the subject matter of the disclosure.



FIG. 2B is a diagram illustrating axial electric fields generated by interactions between electrode pairs, in accordance with embodiments of the subject matter of the disclosure.



FIG. 2C is a diagram illustrating circumferential electric fields generated by interactions between electrode pairs in the catheter, in accordance with embodiments of the subject matter of the disclosure.



FIG. 3 is a diagram illustrating an IRE pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence, in accordance with embodiments of the subject matter of the disclosure.



FIG. 4 is a flow chart diagram illustrating a method of ablating targeted tissue in a patient by irreversible electroporation, in accordance with embodiments of the subject matter of the disclosure.





While the disclosure is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the disclosure to the particular embodiments described. On the contrary, the disclosure is intended to cover all modifications, equivalents, and alternatives falling within the scope of the disclosure as defined by the appended claims.


DETAILED DESCRIPTION

The following detailed description is exemplary in nature and is not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the following description provides some practical illustrations for implementing exemplary embodiments of the present invention. Examples of constructions, materials, and/or dimensions are provided for selected elements. Those skilled in the art will recognize that many of the noted examples have a variety of suitable alternatives.



FIG. 1 is a diagram illustrating an exemplary clinical setting 10 for treating a patient 20, and for treating a heart 30 of the patient 20, using an electrophysiology system 50, in accordance with embodiments of the subject matter of the disclosure. The electrophysiology system 50 includes an electroporation system 60 and an electro-anatomical mapping (EAM) system 70, which includes a localization field generator 80, a mapping and navigation controller 90, and a display 92. Also, the clinical setting 10 includes additional equipment such as imaging equipment 94 (represented by the C-arm) and various controller elements, such as a foot controller 96, configured to allow an operator to control various aspects of the electrophysiology system 50. As will be appreciated by the skilled artisan, the clinical setting 10 may have other components and arrangements of components that are not shown in FIG. 1.


The electroporation system 60 includes an electroporation catheter 105, an introducer sheath 110, a surface patch electrode 115, and an electroporation generator 130. Also, in embodiments, the electroporation system 60 includes an accelerometer 117, where the accelerometer 117 can be a separate sensor or part of the surface electrode patch 115. Additionally, the electroporation system 60 includes various connecting elements (e.g., cables, umbilicals, and the like) that operate to functionally connect the components of the electroporation system 60 to one another and to the components of the EAM system 70. This arrangement of connecting elements is not of critical importance to the present disclosure, and one skilled in the art will recognize that the various components described herein may be interconnected in a variety of ways.


In embodiments, the electroporation system 60 is configured to deliver electric field energy to targeted tissue in the patient's heart 30 to create tissue apoptosis, rendering the tissue incapable of conducting electrical signals. The electroporation generator 130 is configured to control functional aspects of the electroporation system 60. In embodiments, the electroporation generator 130 is operable as a pulse generator for generating and supplying pulse sequences to the electroporation catheter 105 and the surface patch electrode 115, as described in greater detail herein. In embodiments, the electroporation generator 130 is operable to receive sensed signals from the accelerometer 117 and based on the received sensed signals act as a pulse generator for generating and supplying pulse sequences to the electroporation catheter 105 and the surface patch electrode 115, as described in greater detail herein.


In embodiments, the electroporation generator 130 includes one or more controllers, microprocessors, and/or computers that execute code out of memory to control and/or perform the functional aspects of the electroporation catheter system 60. In embodiments, the memory may be part of the one or more controllers, microprocessors, and/or computers, and/or part of memory capacity accessible through a network, such as the world wide web.


In embodiments, the introducer sheath 110 is operable to provide a delivery conduit through which the electroporation catheter 105 may be deployed to the specific target sites within the patient's heart 30. It will be appreciated, however, that the introducer sheath 110 is illustrated and described herein to provide context to the overall electrophysiology system 50, but it is not critical to the novel aspects of the various embodiments described herein.


The EAM system 70 is operable to track the location of the various functional components of the electroporation system 60, and to generate high-fidelity three-dimensional anatomical and electro-anatomical maps of the cardiac chambers of interest. In embodiments, the EAM system 70 may be the RHYTHMIA™ HDx mapping system marketed by Boston Scientific Corporation. Also, in embodiments, the mapping and navigation controller 90 of the EAM system 70 includes one or more controllers, microprocessors, and/or computers that execute code out of memory to control and/or perform functional aspects of the EAM system 70, where the memory, in embodiments, may be part of the one or more controllers, microprocessors, and/or computers, and/or part of memory capacity accessible through a network, such as the world wide web.


As will be appreciated by the skilled artisan, the depiction of the electrophysiology system 50 shown in FIG. 1 is intended to provide a general overview of the various components of the system 50 and is not in any way intended to imply that the disclosure is limited to any set of components or arrangement of the components. For example, the skilled artisan will readily recognize that additional hardware components, e.g., breakout boxes, workstations, and the like, may and likely will be included in the electrophysiology system 50.


The EAM system 70 generates a localization field, via the field generator 80, to define a localization volume about the heart 30, and one or more location sensors or sensing elements on the tracked device(s), e.g., the electroporation catheter 105, generate an output that may be processed by the mapping and navigation controller 90 to track the location of the sensor, and consequently, the corresponding device, within the localization volume. In the illustrated embodiment, the device tracking is accomplished using magnetic tracking techniques, whereby the field generator 80 is a magnetic field generator that generates a magnetic field defining the localization volume, and the location sensors on the tracked devices are magnetic field sensors.


In other embodiments, impedance tracking methodologies may be employed to track the locations of the various devices. In such embodiments, the localization field is an electric field generated, for example, by an external field generator arrangement, e.g., surface electrodes, by intra-body or intra-cardiac devices, e.g., an intracardiac catheter, or both. In these embodiments, the location sensing elements may constitute electrodes on the tracked devices that generate outputs received and processed by the mapping and navigation controller 90 to track the location of the various location sensing electrodes within the localization volume.


In embodiments, the EAM system 70 is equipped for both magnetic and impedance tracking capabilities. In such embodiments, impedance tracking accuracy can, in some instances, be enhanced by first creating a map of the electric field induced by the electric field generator within the cardiac chamber of interest using a probe equipped with a magnetic location sensor, as is possible using the aforementioned RHYTHMIA HDx™ mapping system. One exemplary probe is the INTELLAMAP ORION™ mapping catheter marketed by Boston Scientific Corporation.


Regardless of the tracking methodology employed, the EAM system 70 utilizes the location information for the various tracked devices, along with cardiac electrical activity acquired by, for example, the electroporation catheter 105 or another catheter or probe equipped with sensing electrodes, to generate, and display via the display 92, detailed three-dimensional geometric anatomical maps or representations of the cardiac chambers as well as electro-anatomical maps in which cardiac electrical activity of interest is superimposed on the geometric anatomical maps. Furthermore, the EAM system 70 may generate a graphical representation of the various tracked devices within the geometric anatomical map and/or the electro-anatomical map.


While the EAM system 70 is shown in combination with the electroporation system 60 to provide a comprehensive depiction of an exemplary clinical setting 10, the EAM system 70 is not critical to the operation and functionality of the electroporation system 60. That is, in embodiments, the electroporation system 60 can be employed independently of the EAM system 70 or any comparable electro-anatomical mapping system.


In the illustrated embodiment, the electroporation catheter 105 includes a handle 105a, a shaft 105b, and an electroporation electrode arrangement 150, which is described further hereinafter. The handle 105a is configured to be operated by a user to position the electroporation electrode arrangement 150 at the desired anatomical location. The shaft 105b has a distal end 105c and generally defines a longitudinal axis of the electroporation catheter 105. As shown, the electroporation electrode arrangement 150 is located at or proximate the distal end 105c of the shaft 105b. In embodiments, the electroporation electrode arrangement 150 is electrically coupled to the electroporation generator 130, to receive electrical pulse sequences or pulse trains, thereby selectively generating electrical fields for ablating the target tissue by irreversible electroporation.


In embodiments, the surface patch electrode 115 includes a conductive electrode that can be attached to the body of the patient 20, such as to the thorax of the patient. The surface patch electrode 115, including the conductive electrode, is electrically coupled to the electroporation generator 130 to act as a return path or sink for electrical energy in the system and to receive electrical pulse sequences or pulse trains from the electroporation generator 130, thereby acting as a source for electrical energy and selectively generating electrical fields for ablating the target tissue by irreversible electroporation. In embodiments, the surface patch electrode 115 acts as a return or sink for electrical energy received by the electroporation catheter 105 and the electroporation electrode arrangement 150. In embodiments, the surface patch electrode 115 acts as a source for electrical energy and the electroporation catheter 105 including the electroporation electrode arrangement 150 acts as the return or sink for the sourced electrical energy.


The electroporation system 60 is operable to generate an IRE pulse sequence that includes a preconditioning (pretreatment) pulse sequence and an electroporation pulse sequence. The IRE pulse sequence is configured to ablate targeted tissue. In embodiments, the preconditioning pulse sequence is a series of electrical pulses that ramp up in magnitude to tetanize skeletal muscle tissue and to provide electrolysis near targeted tissue. In embodiments, the electroporation pulse sequence is a series of electroporation pulses configured to cause irreversible damage to the targeted tissue.


In embodiments, the electroporation system 60 includes the accelerometer 117 that may be attached to the body of the patient 20, such as to the thorax of the patient, and electrically coupled to the electroporation generator 130. The accelerometer 117 is configured to sense contraction of the skeletal muscle system of the patient to detect tetany. The signals from the accelerometer 117 are received by the electroporation generator 130, which processes the signals to determine whether the skeletal muscle system of the patient is contracting and whether tetany has been achieved. In embodiments, the electroporation generator 130 is configured to provide the electroporation pulse sequence only after tetany has been achieved in the patient.


In embodiments, the electroporation system 60 acts as a closed system with the surface accelerometer 117 monitoring chest vibrations and the electroporation generator 130 modulating pulses until tetany is achieved and then the electroporation generator 130 delivers the electroporation pulses. Also, in embodiments, the local impedance of the target tissue and tissue surrounding the target tissue can be measured during this time to calculate pre-ablation and post-ablation values for evaluation of the lesion efficacy.



FIGS. 2A-2C show features of the electroporation catheter 105 that includes the electroporation electrode arrangement 150 according to exemplary embodiments. In the illustrated embodiment in FIG. 2A, the electroporation electrode arrangement 150 includes a plurality of electrodes 201a, 201b, 201c, 201d, 201e, and 201f arranged in a three-dimensional electrode array, such that respective ones of the electrodes 201a, 201b, 201c, 201d, 201e, and 201f are spaced from one another axially (i.e., in the direction of the longitudinal axis LA), circumferentially about the longitudinal axis LA and/or radially relative to the longitudinal axis LA. In some embodiments, the electrodes 201a, 201b, 201c, 201d, 201e, and 201f are each individually, selectively addressable via the electroporation generator 130 (FIG. 1) to define a plurality of anode-cathode electrode pairs, each capable of receiving an electrical pulse sequence from the electroporation generator 130 and, consequently, creating an electric field capable of selectively targeting tissue via electroporation, including ablating target tissue via IRE. FIG. 2A schematically illustrates interactions (e.g., current flows forming electric fields) between electrode pairs formed between electrodes 201 (e.g., 201a, 201b, 201c, 201d, 201e, and 201f) included in the electroporation catheter 105. In this figure, interactions are shown as paired arrows (e.g., a-d, b-e, and d-f) indicating current flows between electrodes 201. And electrode pairs (e.g., 201a and 201d, 201b and 201e, and 201d and 201f) are shown with their respective current flows (e.g., a-d, b-e, and d-f) labeled.



FIG. 2B is a diagram illustrating electric fields 210 generated by interactions between electrode pairs in the electroporation catheter 105. In this figure, axially oriented electric fields 210 are shown positioned at an ostium 221 between the left atrium 223 and the left inferior pulmonary vein 225. In embodiments, the axially oriented electric fields 210 are produced by delivering electrical pulses to axially spaced anodes and cathodes.



FIG. 2C is also a diagram illustrating electric fields 210 generated by interactions between electrode pairs in the electroporation catheter 105. But here, the electric fields 210 are circumferentially oriented. In embodiments, the circumferentially oriented electric fields 210 are produced by delivering electrical pulses to circumferentially spaced anodes (“A”) and cathodes (“C”).



FIGS. 2A-2C show that multiple electric fields 210 may be generated simultaneously and/or sequentially and in axial and circumferential orientations. For example, in embodiments, axially and circumferentially oriented electric fields 210 can be generated non-simultaneously in a pre-defined sequence by selectively controlling the timing of the delivery of the electric pulses to the respective electrodes 201. In addition, it is understood that intermittently generated electric fields 210 caused by staggered interactions between sets of electrode pairs and electric field orientations other than axial and circumferential are not beyond the scope of this disclosure.


As may be seen in FIG. 2A, the electroporation electrode arrangement 150 may include a plurality of individually addressable electrodes 201 (e.g., anodes or cathodes) arranged to selectively define a plurality of electrode pairs (e.g., anode-cathode pairs). Each anode-cathode pair may be configured to generate an electric field when a pulse sequence is delivered thereto. The plurality of anode-cathode pairs may include at least two of a first anode-cathode pair, a second anode-cathode pair, and a third anode-cathode pair. The first anode-cathode pair may be arranged to generate a first electric field oriented generally circumferentially relative to the longitudinal axis when a first pulse sequence is delivered thereto. The second anode-cathode pair may be arranged to generate a second electric field oriented generally in a same direction as the longitudinal axis when a second pulse sequence is delivered thereto. The third anode-cathode pair may be arranged to generate a third electric field oriented generally transverse to the longitudinal axis when a third pulse sequence is delivered thereto. In embodiments, any combination of the first, second, and third pulse sequences may be delivered simultaneously or intermittently and may take a variety of forms.


In embodiments, the electroporation electrode arrangement 150 may be configured to structurally arrange the electrodes 201a, 201b, 201c, 201d, 201e, and 201f into a distally-located first region and a more proximally-located second region. As such, electrode pairs may be formed across various electrodes 201 in the electroporation electrode arrangement 150 between first and second regions. For example, the electrodes 201d and 201f may be configured to form an electrode pair. Similarly, the electrodes 201a and 201d or electrodes 201b and 201e or the combination thereof may be selected to form respective electrode pairs. Thus, the electrode pairs may comprise axially spaced electrodes, transversely spaced electrodes, or circumferentially spaced electrodes. Additionally, in embodiments, a given electrode (e.g., 201d) may serve as a common electrode in at least two electrode pairs to generate electric fields 210.



FIG. 2B shows a diagram of exemplary electric fields 210 that may be generated by the electroporation electrode arrangement 150. The electroporation electrode arrangement 150 may be configured to generate a multidirectional electric field 210 when at least one pulse sequence is delivered thereto. The multidirectional electric field 210 may include at least two of the following directions relative to the longitudinal axis: generally axial, circumferential, and transverse. As used herein, transverse may mean at any non-parallel angle relative to the longitudinal axis. As described elsewhere herein, the electroporation electrode arrangement 150 may be configured to operatively couple to an electroporation generator that is configured to generate the at least one pulse sequence. The electroporation electrode arrangement 150 may be configured to receive the at least one pulse sequence from the electroporation generator. Thus, the electroporation electrode arrangement 150 and the electroporation generator may be in operative communication with each other. In this disclosure, such communication may be used to generate electric fields 210 that are at least substantially gapless.


Undesired gaps in electric fields 210 generated by the electroporation electrode arrangement 150 may be limited or at least substantially eliminated. Such gaps may potentially lead to lesion gaps and therefore require multiple repositions of a catheter, for example. Overlapping electric fields 210 may at least substantially limit the number of such gaps. In embodiments, at least some the electric fields 210 generated in the first pulse sequence set may overlap at least partially with each other. For example, adjacent electric fields 210 (e.g., axial, transverse, and/or circumferential) in a combined electric field 211 may intersect one another so that there are limited to no gaps in the combined electric field 211. Overlapping may occur at or near the periphery of adjacent electric fields 210 or may occur over a preponderance or majority of one or more adjacent electric fields 210. In this disclosure, adjacent means neighboring electrodes 201 or electrodes 201 otherwise near each other. The electroporation generator may be configured to generate pulse sequences used in generating overlapping electric fields.


The configuration of the electroporation electrode arrangement 150 in the various embodiments may take on any form, whether now known or later developed, suitable for a three-dimensional electrode structure. In exemplary embodiments, the electroporation electrode arrangement 150 may be in the form of a splined basket catheter, with respective electrodes 201a, 201b, 201c, 201d, 201e, and 201f positioned on a plurality of splines in any manner known in the art. In embodiments, the electroporation electrode arrangement 150 can be formed on an expandable balloon, e.g., with electrodes formed on flexible circuit branches or individual traces disposed on the balloon surface. In other embodiments, the electroporation electrode arrangement 150 may be in the form of an expandable mesh. In short, the particular structure used to form the electroporation electrode arrangement 150 is not critical to the embodiments of the present disclosure.



FIG. 3 is a diagram illustrating an ablation energy application sequence 300, also referred to herein as an IRE pulse sequence 300, that includes a preconditioning pulse sequence 302 and an electroporation pulse sequence 304, in accordance with exemplary embodiments. The preconditioning pulse sequence 302 is a series of pulses 306 that ramp up in magnitude from a lower voltage to a higher voltage. The electroporation pulse sequence 304 is a series of high energy electroporation pulses 308 having large positive and/or negative voltage values.


The electroporation system 60 is configured to deliver the preconditioning pulse sequence 302, which delivers the series or sequence of pulses 306 for achieving tetany and for generating electrolysis. In FIG. 3, only three pulses 306 of the preconditioning pulse sequence 302 are pointed to for clarity in the figure, however, in embodiments, the sequence of pulses 306 includes all the pulses in the preconditioning pulse sequence 302. The electroporation system 60 is further configured to deliver the electroporation pulse sequence 304, i.e., electroporation ablation energy, in the series of electroporation pulses 308 to ablate the targeted tissue. In embodiments, all pulses in the IRE pulse sequence 300 are delivered within the refractory period of the heart, such as within 250-330 milliseconds.


The sequence of pulses 306 is a series of monophasic pulses that ramp up in magnitude from a lower voltage to a higher voltage over time. The ramping of voltage causes relatively slower recruitment of skeletal muscles culminating in the tetanic skeletal muscle contraction preceding the higher voltage electroporation pulses 308 in the electroporation pulse sequence 304. Each of the pulses 306, or at least some of the pulses 306, also have features that promote electrolysis, such as including a monophasic exponentially decaying waveform 310 (or drooping waveform) on the back side of the pulse 306. In FIG. 3, only three of the exponentially decaying waveforms 310 in the preconditioning pulse sequence 302 are pointed to for clarity in the figure, however, in embodiments, all the pulses in the preconditioning pulse sequence 302 include exponentially decaying waveforms 310. In embodiments, the pulses 306 may not be completely monophasic, but include at least some asymmetrical phases that are charge balanced with both positive and negative components. In some embodiments, the duration of the pulses 306 is between 1 millisecond (ms) and 60 ms and, in some embodiments, the waveform tilt/droop/exponential decay is in the range of 20 to 80% of the leading edge.


The pulses 306 can have a number of different characteristics. In embodiments, the pulses 306 in the preconditioning pulse sequence 302 are provided at a selected frequency, such as 1 kilohertz. In some embodiments, this frequency is in the range of 200-1000 Hz. In embodiments, the pulses 306 are ramped up in voltage from 0 volts to between 5 and 100 volts and, in some embodiments, the amplitude reaches between 100 and 1000 volts. Also, in embodiments, ramping rates can be incrementing 1% to 30% of the preceding pulse. In some embodiments, the preconditioning pulse sequence 302 is applied in a 100-250 millisecond sequence duration.


The preconditioning pulse sequence 302 preconditions the body for electroporation in at least two ways. First, the preconditioning pulse sequence 302 acts as a series of tetanizing skeletal muscle pulses 306 that cause tetany, i.e., contraction of the skeletal muscles of the patient's body, prior to receiving the higher voltage electroporation pulse sequence 304. Ramping the pulses 306 up in magnitude from a lower voltage to a higher voltage over time causes or contributes to bringing about tetany. This SMS prepares the patient for the higher voltage electroporation pulses 308 in the electroporation pulse sequence 304, which otherwise may shock the patient or be a painful experience for the patient. Second, the preconditioning pulse sequence 302 acts as a series of electrolysis inducing pulses 306 that cause electrolysis near the target tissue. This results in creating a cytotoxic environment near the target tissue, such that smaller electroporation pulses can be used to permeabilize the target tissue and cause cell death, creating larger lesions with smaller electroporation pulses.


This synergistic electrolysis is caused by applying relatively long, low voltage pulses, such as the preconditioning pulse sequence 302, to the target area. In particular, the exponentially decaying waveforms 310 (or drooping waveforms) on the back side of the pulses 306 of the preconditioning pulse sequence 302 bring about electrolysis near the electrodes. In further explanation, synergistic electrolysis occurs when new chemical species are generated at the interface of the electrodes as a result of electron transfer between the electrodes and the ions in solution. The new chemical species diffuse away from the electrodes, into tissue, in a process driven by electrochemical potentials. In physiological solutions, electrolytic reactions yield changes in pH, resulting in an acidic region near the anode and a basic region near the cathode. The cytotoxic environment developing due to local changes in pH, and the presence of some of the new chemical species formed during electrolysis of the solution, along with permeabilization of electroporation cause cell death.


In exemplary embodiments, the preconditioning pulse sequence 302 is delivered as a series of unipolar electrical pulses 306. The surface patch electrode 115, attached to the thorax of the patient 20, receives the electrical pulses from the electroporation generator 130 and sources the electrical energy, where the surface patch electrode 115 acts as a source electrode for the electrical pulses. One or more electrodes on the electroporation catheter 105 sink the electrical energy that is sourced by the surface patch electrode 115, where the one or more electrodes on the electroporation catheter 105 act as a sink for the electrical pulses. This causes the skeletal muscles of the patient to contract, reaching tetany, and generates the synergistic electrolysis near the targeted tissue, where electrodes of the electroporation catheter 105 are situated near the targeted tissue.


In other embodiments, one or more electrodes on the electroporation catheter 105 receives the pulses 306 from the electroporation generator 130 and sources the electrical energy, such that the one or more electrodes on the electroporation catheter 105 act as a source electrode for the electrical pulses 306. The surface patch electrode 115, attached to the thorax of the patient 20, sinks the electrical energy that is sourced by the one or more electrodes on the electroporation catheter 105, such that the surface patch electrode 115 acts as a sink for the electrical pulses.


After delivering at least some of the preconditioning pulse sequence 302, the electroporation system 60 is configured to deliver the electroporation pulse sequence 304, i.e., electroporation ablation energy, to ablate the targeted tissue. The electroporation pulse sequence 304 includes high energy electroporation pulses 308 of short duration. As illustrated, the electroporation pulses 308 of the electroporation pulse sequence 304 are biphasic, including, for example, both positive pulses and negative pulses. In embodiments, the electroporation pulses 308 may be positive 1000 volts and negative 1000 volts. In other embodiments, the electroporation pulses 308 can be monophasic, including, for example, all positive pulses or all negative pulses.


With at least some of the pulses 206 of the preconditioning pulse sequence 302 applied prior to applying the electroporation pulses 308, electrolysis near or at the targeted tissue makes it possible to use electroporation pulses 308 that are lower in amplitude, such as from 250 volts/centimeter (V/cm) to 1000 V/cm, than what is normally or otherwise necessary when using electroporation pulses alone (500 V/cm to 2,500 V/cm).


As illustrated, the electroporation pulses 308 of the electroporation pulse sequence 304 are delivered within the series of pulses 306 of the preconditioning pulse sequence 302. In other embodiments, the electroporation generator 130 can be configured to deliver the electroporation pulses 308 of the electroporation pulse sequence 304 after all the pulses 306 of the preconditioning pulse sequence 302 have been delivered.


The electroporation pulses 308 of the electroporation pulse sequence 304 can be either unipolar pulses or bipolar pulses. In embodiments, pairs of electrodes (or electrode sets) on the electroporation catheter 105 are selected to deliver bipolar pulses between the selected pairs of electrodes. Each electrode of the pairs of electrodes can act as a source electrode and each electrode of the pairs of electrodes can act as a sink, to deliver the electrical ablation energy to the targeted tissue.


In other embodiments, to provide unipolar pulses, one or more electrodes on the electroporation catheter 105 receives the electroporation pulses 308 of the electroporation pulse sequence 304 from the electroporation generator 130 and sources the electrical energy, such that the one or more electrodes on the electroporation catheter 105 act as a source electrode for the electrical pulses. The surface patch electrode 115, attached to the thorax of the patient 20, sinks the electrical energy that is sourced by the one or more electrodes on the electroporation catheter 105, such that the surface patch electrode 115 acts as a sink for the electrical pulses.


In embodiments, the electroporation system 60 includes the accelerometer 117 that is configured to sense contraction of the skeletal muscles of the patient, such as contraction of the patient's chest muscles, to detect tetany. The signals from the accelerometer 117 are received by the electroporation generator 130, which processes the signals to determine whether the skeletal muscle system of the patient is contracting and whether tetany has been achieved. In embodiments, the electroporation generator 130 is configured to provide the electroporation pulse sequence 304 only after tetany has been achieved in the patient. The electroporation generator 130 may provide the electroporation pulse sequence 304 during the preconditioning pulse sequence 302 or after the preconditioning pulse sequence 302.


Thus, the electroporation system 60 acts as a closed system with the surface accelerometer 117 monitoring chest vibrations and the electroporation generator 130 modulating pulses 306 until tetany is achieved and then delivering the electroporation pulses 308. Also, in embodiments, the local impedance of the target tissue and tissue surrounding the target tissue can be measured during this time to calculate pre-ablation and post-ablation values for evaluation of the lesion efficacy.


By applying at least some of the pulses 306 in the preconditioning pulse sequence 302 prior to delivering the electroporation pulses 308 of the electroporation pulse sequence 304, tetany or a contracting of the skeletal muscles of the patient can be achieved and, via electrolysis, a cytotoxic environment can be established near or adjacent the targeted tissue prior to delivering the electroporation pulses 308 of the electroporation pulse sequence 304. This results in being able to use lower energy electroporation pulses 308 and/or fewer electroporation pulses 308 to create the same size lesion as may be created using much more energetic or many more electroporation pulses 308 without the preconditioning pulse sequence 302.



FIG. 4 is a flow chart diagram illustrating a method of ablating targeted tissue in a patient by irreversible electroporation, in accordance with embodiments of the subject matter of the disclosure. Such a method and other related methods of ablating targeted tissue in a patient by irreversible electroporation are disclosed herein.


The method includes delivering an IRE (irreversible electroporation) pulse sequence that includes delivering a preconditioning pulse sequence at 402 and delivering an electroporation pulse sequence at 404. In embodiments, the electroporation pulse sequence is delivered during or within the preconditioning pulse sequence. In other embodiments, the electroporation pulse sequence is delivered after the preconditioning pulse sequence has stopped. In exemplary embodiments, the IRE pulse sequence, including the preconditioning pulse sequence and the electroporation pulse sequence, is delivered to the patient in one or more of a refractory time of the heart of the patient, less than 330 milliseconds, and in a 100-250 millisecond window.


Delivering the preconditioning pulse sequence at 402 includes delivering the preconditioning pulse sequence between a surface patch electrode and one or more catheter electrodes on a catheter to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient. In embodiments, the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the surface patch electrode and sunk through the one or more catheter electrodes. In other embodiments, the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the one or more catheter electrodes and sunk through the surface patch electrode. Also, in embodiments, the preconditioning pulse sequence includes preconditioning pulses that are monophasic.


The preconditioning pulse sequence includes preconditioning pulses delivered at a selected frequency and ramped up in voltage from a lower voltage to a higher voltage over time. In embodiments, the preconditioning pulse sequence includes preconditioning pulses delivered at about 1 kilohertz. Also, in embodiments, the preconditioning pulse sequence includes preconditioning pulses ramped up in voltage from 0 volts to between 5 and 100 volts. Ramping up the voltage of the pulse from a lower voltage to a higher voltage over time, contributes to causing tetanizing skeletal muscle contraction in the patient. Also, the preconditioning pulse sequence includes preconditioning pulses that include an exponentially decaying backside waveform that causes or contributes to electrolysis near the targeted tissue.


Delivering an electroporation pulse sequence at 404 includes delivering the electroporation pulse sequence to catheter electrodes on the catheter to cause irreversible electroporation ablation of the targeted tissue. In embodiments, the electroporation pulse sequence includes bipolar electrical pulses delivered to one or more catheter electrode pairs of the catheter electrodes. In other embodiments, the electroporation pulse sequence includes unipolar electrical pulses delivered between the surface patch electrode and one or more catheter electrodes on the catheter.


In embodiments, the method further includes monitoring the accelerometer 117 on the patient, which is configured to sense contraction of the skeletal muscles of the patient, such as contraction of the patient's chest muscles, to detect tetany. In a closed loop system, the signals from the accelerometer 117 are received by the electroporation generator 130, which processes the signals to determine whether the skeletal muscle system of the patient is contracting and whether tetany has been achieved. In embodiments, the electroporation generator 130 is configured to provide the electroporation pulse sequence only after tetany has been achieved in the patient, which may be during the preconditioning pulse sequence or after the preconditioning pulse sequence.


Also, in embodiments, the method includes monitoring the local impedance of the target tissue and tissue surrounding the target tissue to calculate pre-ablation and post-ablation values for evaluation of the lesion efficacy.


Various modifications and additions may be made to the exemplary embodiments discussed without departing from the scope of the present disclosure. For example, while the embodiments described above refer to particular features, the scope of this disclosure also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present disclosure is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.

Claims
  • 1. An electroporation ablation system for treating targeted tissue in a patient, the electroporation ablation system comprising: an ablation catheter including: a handle;a shaft having a distal end; andcatheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to electrical pulses; andan electroporation generator operatively coupled to the catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to one or more of the catheter electrodes,wherein the preconditioning pulse sequence includes preconditioning electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.
  • 2. The electroporation ablation system of claim 1, comprising a surface patch electrode attached to the patient and configured to generate electric fields in the patient in response to the electrical pulses.
  • 3. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the surface patch electrode and sunk through the one or more of the catheter electrodes.
  • 4. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes unipolar electrical pulses that are sourced from the one or more of the catheter electrodes and sunk through the surface patch electrode.
  • 5. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes bipolar electrical pulses that are sourced from at least one of the one or more catheter electrodes and sunk through at least another one of the one or more catheter electrodes.
  • 6. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes preconditioning pulses delivered at a selected frequency.
  • 7. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes preconditioning pulses ramped up in voltage from a lower voltage to a higher voltage over time.
  • 8. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes preconditioning pulses that include an exponentially decaying backside waveform configured to cause electrolysis near the targeted tissue.
  • 9. The electroporation ablation system of claim 1, wherein the preconditioning pulse sequence includes preconditioning pulses that are monophasic.
  • 10. The electroporation ablation system of claim 1, wherein the irreversible electroporation pulse sequence, including the preconditioning pulse sequence and the electroporation pulse sequence, is delivered to the patient in one or more of a refractory time of a heart of the patient, for less than 330 milliseconds, and in a 100-250 millisecond window.
  • 11. The electroporation ablation system of claim 1, wherein the electroporation pulse sequence is delivered within the preconditioning pulse sequence.
  • 12. The electroporation ablation system of claim 1, wherein the electroporation pulse sequence includes bipolar electrical pulses delivered to one or more catheter electrode pairs of the one or more of the catheter electrodes.
  • 13. The electroporation ablation system of claim 1, comprising an accelerometer configured to monitor skeletal muscle stimulation of the patient and wherein the electroporation ablation system is a closed loop system such that the electroporation generator is configured to deliver the preconditioning pulse sequence, detect tetany in the patient, and then deliver the electroporation pulse sequence, and wherein local impedance is measured to calculate pre-ablation and post-ablation values to evaluate lesion efficacy.
  • 14. An electroporation ablation system for treating targeted tissue in a patient, the electroporation ablation system comprising: an ablation catheter including: a handle;a shaft having a distal end; andcatheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to receiving electrical pulses; andan electroporation generator operatively coupled to multiple electrodes including one or more of a surface patch electrode and one or more of the catheter electrodes and configured to deliver the electrical pulses in an irreversible electroporation pulse sequence that includes a preconditioning pulse sequence and an electroporation pulse sequence to the multiple electrodes, wherein the electroporation generator is configured to deliver the electroporation pulse sequence during the preconditioning pulse sequence;wherein the preconditioning pulse sequence includes preconditioning electrical pulses configured to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient.
  • 15. The electroporation ablation system of claim 14, wherein the electroporation pulse sequence includes bipolar electrical pulses delivered to selected pairs of the one or more catheter electrodes.
  • 16. A method of ablating targeted tissue in a patient by irreversible electroporation, the method comprising: delivering an irreversible electroporation pulse sequence comprising: delivering a preconditioning pulse sequence between multiple electrodes including one or more of a surface patch electrode and one or more catheter electrodes on a catheter to cause electrolysis near the targeted tissue and tetanizing skeletal muscle stimulation in the patient; anddelivering an electroporation pulse sequence to the multiple electrodes to cause irreversible electroporation ablation of the targeted tissue.
  • 17. The method of claim 16, wherein delivering a preconditioning pulse sequence includes delivering electrical pulses that ramp up in voltage from a lower voltage to a higher voltage over time and wherein one or more of the electrical pulses include an exponentially decaying backside waveform.
  • 18. The method of claim 16, wherein the electroporation pulse sequence is delivered during the preconditioning pulse sequence.
  • 19. The method of claim 16, comprising monitoring an accelerometer on the patient and in a closed loop system, delivering the preconditioning pulse sequence to achieve the tetany in the patient, detecting tetany in the patient via the accelerometer, and delivering the electroporation pulse sequence after tetany has been achieved.
CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to Provisional Application No. 63/085,452, filed Sep. 30, 2020, which is herein incorporated by reference in its entirety.

US Referenced Citations (673)
Number Name Date Kind
4200104 Harris Apr 1980 A
4470407 Hussein Sep 1984 A
4739759 Rexroth et al. Apr 1988 A
5234004 Hascoet et al. Aug 1993 A
5242441 Avitall Sep 1993 A
5257635 Langberg Nov 1993 A
5281213 Milder et al. Jan 1994 A
5304214 Deford et al. Apr 1994 A
5306296 Wright et al. Apr 1994 A
5334193 Nardella Aug 1994 A
5341807 Nardella Aug 1994 A
5342301 Saab Aug 1994 A
5398683 Edwards et al. Mar 1995 A
5443463 Stern et al. Aug 1995 A
5454370 Avitall Oct 1995 A
5515848 Corbett et al. May 1996 A
5531685 Hemmer et al. Jul 1996 A
5545161 Imran Aug 1996 A
5558091 Acker et al. Sep 1996 A
5578040 Smith Nov 1996 A
5617854 Munsif Apr 1997 A
5624430 Eton et al. Apr 1997 A
5662108 Budd et al. Sep 1997 A
5667491 Pliquett et al. Sep 1997 A
5672170 Cho et al. Sep 1997 A
5700243 Narciso, Jr. Dec 1997 A
5702438 Avitall Dec 1997 A
5706823 Wodlinger Jan 1998 A
5722400 Ockuly et al. Mar 1998 A
5722402 Swanson et al. Mar 1998 A
5749914 Janssen May 1998 A
5779699 Lipson Jul 1998 A
5788692 Campbell et al. Aug 1998 A
5810762 Hofmann Sep 1998 A
5833710 Jacobson Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5836942 Netherly et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5843154 Osypka Dec 1998 A
5849028 Chen Dec 1998 A
5863291 Schaer Jan 1999 A
5868736 Swanson et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5876336 Swanson et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5895404 Ruiz Apr 1999 A
5899917 Edwards et al. May 1999 A
5904709 Arndt et al. May 1999 A
5916158 Webster, Jr. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5928269 Alt Jul 1999 A
5928270 Ramsey, III Jul 1999 A
6002955 Willems et al. Dec 1999 A
6006131 Cooper et al. Dec 1999 A
6009351 Flachman Dec 1999 A
6014579 Pomeranz et al. Jan 2000 A
6029671 Stevens et al. Feb 2000 A
6033403 Tu et al. Mar 2000 A
6035238 Ingle et al. Mar 2000 A
6045550 Simpson et al. Apr 2000 A
6059779 Mills May 2000 A
6068653 LaFontaine May 2000 A
6071274 Thompson et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6074389 Levine et al. Jun 2000 A
6076012 Swanson et al. Jun 2000 A
6090104 Webster, Jr. Jul 2000 A
6096036 Bowe et al. Aug 2000 A
6113595 Muntermann Sep 2000 A
6119041 Pomeranz et al. Sep 2000 A
6120500 Bednarek et al. Sep 2000 A
6146381 Bowe et al. Nov 2000 A
6164283 Lesh Dec 2000 A
6167291 Barajas et al. Dec 2000 A
6171305 Sherman Jan 2001 B1
6216034 Hofmann et al. Apr 2001 B1
6219582 Hofstad et al. Apr 2001 B1
6223085 Dann et al. Apr 2001 B1
6231518 Grabek et al. May 2001 B1
6245064 Lesh et al. Jun 2001 B1
6251107 Schaer Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6272384 Simon et al. Aug 2001 B1
6287306 Kroll et al. Sep 2001 B1
6314963 Vaska et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6350263 Wetzig et al. Feb 2002 B1
6370412 Armoundas et al. Apr 2002 B1
6391024 Sun et al. May 2002 B1
6447505 McGovern et al. Sep 2002 B2
6464699 Swanson Oct 2002 B1
6470211 Ideker et al. Oct 2002 B1
6502576 Lesh Jan 2003 B1
6503247 Swartz et al. Jan 2003 B2
6517534 McGovern et al. Feb 2003 B1
6527724 Fenici Mar 2003 B1
6527767 Wang et al. Mar 2003 B2
6592581 Bowe Jul 2003 B2
6595991 Toellner et al. Jul 2003 B2
6607520 Keane Aug 2003 B2
6623480 Kuo et al. Sep 2003 B1
6638278 Falwell et al. Oct 2003 B2
6666863 Wentzel et al. Dec 2003 B2
6669693 Friedman Dec 2003 B2
6702811 Stewart et al. Mar 2004 B2
6719756 Muntermann Apr 2004 B1
6723092 Brown et al. Apr 2004 B2
6728563 Rashidi Apr 2004 B2
6743225 Sanchez et al. Jun 2004 B2
6743226 Cosman et al. Jun 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6764486 Natale Jul 2004 B2
6780181 Kroll et al. Aug 2004 B2
6805128 Pless et al. Oct 2004 B1
6807447 Griffin, III Oct 2004 B2
6892091 Ben-Haim et al. May 2005 B1
6893438 Hall et al. May 2005 B2
6926714 Sra Aug 2005 B1
6955173 Lesh Oct 2005 B2
6960206 Keane Nov 2005 B2
6960207 Vanney et al. Nov 2005 B2
6972016 Hill et al. Dec 2005 B2
6973339 Govari Dec 2005 B2
6979331 Hintringer et al. Dec 2005 B2
6984232 Vanney et al. Jan 2006 B2
6985776 Kane et al. Jan 2006 B2
7001383 Keidar Feb 2006 B2
7041095 Wang et al. May 2006 B2
7113831 Hooven Sep 2006 B2
7171263 Darvish et al. Jan 2007 B2
7182725 Bonan et al. Feb 2007 B2
7195628 Falkenberg Mar 2007 B2
7207988 Leckrone et al. Apr 2007 B2
7207989 Pike et al. Apr 2007 B2
7229402 Diaz et al. Jun 2007 B2
7229437 Johnson et al. Jun 2007 B2
7250049 Roop et al. Jul 2007 B2
7282057 Surti et al. Oct 2007 B2
7285116 De et al. Oct 2007 B2
7285119 Stewart et al. Oct 2007 B2
7326208 Vanney et al. Feb 2008 B2
7346379 Eng et al. Mar 2008 B2
7367974 Haemmerich et al. May 2008 B2
7374567 Heuser May 2008 B2
7387629 Vanney et al. Jun 2008 B2
7387630 Mest Jun 2008 B2
7387636 Cohn et al. Jun 2008 B2
7416552 Paul et al. Aug 2008 B2
7419477 Simpson et al. Sep 2008 B2
7419489 Vanney et al. Sep 2008 B2
7422591 Phan Sep 2008 B2
7429261 Kunis et al. Sep 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7513896 Orszulak Apr 2009 B2
7527625 Knight et al. May 2009 B2
7578816 Boveja et al. Aug 2009 B2
7588567 Boveja et al. Sep 2009 B2
7623899 Worley et al. Nov 2009 B2
7643876 Zhang et al. Jan 2010 B2
7678108 Chrisitian et al. Mar 2010 B2
7681579 Schwartz Mar 2010 B2
7771421 Stewart et al. Aug 2010 B2
7805182 Weese et al. Sep 2010 B2
7850642 Moll et al. Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7857808 Oral et al. Dec 2010 B2
7857809 Drysen Dec 2010 B2
7869865 Govari et al. Jan 2011 B2
7896873 Hiller et al. Mar 2011 B2
7917211 Zacouto Mar 2011 B2
7918819 Karmarkar et al. Apr 2011 B2
7918850 Govari et al. Apr 2011 B2
7922714 Stevens-Wright Apr 2011 B2
7955827 Rubinsky et al. Jun 2011 B2
8048067 Davalos et al. Nov 2011 B2
8048072 Verin et al. Nov 2011 B2
8100895 Panos et al. Jan 2012 B2
8100900 Prinz et al. Jan 2012 B2
8108069 Stahler et al. Jan 2012 B2
8133220 Lee et al. Mar 2012 B2
8137342 Crossman Mar 2012 B2
8145289 Calabro'et al. Mar 2012 B2
8147486 Honour et al. Apr 2012 B2
8160690 Wilfley et al. Apr 2012 B2
8175680 Panescu May 2012 B2
8182477 Orszulak et al. May 2012 B2
8206384 Falwell et al. Jun 2012 B2
8206385 Stangenes et al. Jun 2012 B2
8216221 Ibrahim et al. Jul 2012 B2
8221411 Francischelli et al. Jul 2012 B2
8226648 Paul et al. Jul 2012 B2
8228065 Wirtz et al. Jul 2012 B2
8235986 Kulesa et al. Aug 2012 B2
8235988 Davis et al. Aug 2012 B2
8251986 Chornenky et al. Aug 2012 B2
8282631 Davalos et al. Oct 2012 B2
8287532 Carroll et al. Oct 2012 B2
8414508 Thapliyal et al. Apr 2013 B2
8430875 Ibrahim et al. Apr 2013 B2
8433394 Harlev et al. Apr 2013 B2
8449535 Deno et al. May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8463368 Harlev et al. Jun 2013 B2
8475450 Govari et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8500733 Watson Aug 2013 B2
8535304 Sklar et al. Sep 2013 B2
8538501 Venkatachalam et al. Sep 2013 B2
8562588 Hobbs et al. Oct 2013 B2
8568406 Harlev et al. Oct 2013 B2
8571635 Mcgee Oct 2013 B2
8571647 Harlev et al. Oct 2013 B2
8585695 Shih Nov 2013 B2
8588885 Hall et al. Nov 2013 B2
8597288 Christian Dec 2013 B2
8608735 Govari et al. Dec 2013 B2
8628522 Ibrahim et al. Jan 2014 B2
8632534 Pearson et al. Jan 2014 B2
8647338 Chornenky et al. Feb 2014 B2
8708952 Cohen et al. Apr 2014 B2
8734442 Cao et al. May 2014 B2
8771267 Kunis et al. Jul 2014 B2
8795310 Fung et al. Aug 2014 B2
8808273 Caples et al. Aug 2014 B2
8808281 Emmons et al. Aug 2014 B2
8834461 Werneth et al. Sep 2014 B2
8834464 Stewart et al. Sep 2014 B2
8868169 Narayan et al. Oct 2014 B2
8876817 Avitall et al. Nov 2014 B2
8880195 Azure Nov 2014 B2
8886309 Luther et al. Nov 2014 B2
8903488 Callas et al. Dec 2014 B2
8920411 Gelbart et al. Dec 2014 B2
8926589 Govari Jan 2015 B2
8932287 Gelbart et al. Jan 2015 B2
8945117 Bencini Feb 2015 B2
8979841 Kunis et al. Mar 2015 B2
8986278 Fung et al. Mar 2015 B2
9002442 Harley et al. Apr 2015 B2
9005189 Davalos et al. Apr 2015 B2
9005194 Oral et al. Apr 2015 B2
9011425 Fischer et al. Apr 2015 B2
9044245 Condie et al. Jun 2015 B2
9055959 Vaska et al. Jun 2015 B2
9072518 Swanson Jul 2015 B2
9078667 Besser et al. Jul 2015 B2
9101374 Hoch et al. Aug 2015 B1
9119533 Ghaffari Sep 2015 B2
9119634 Gelbart et al. Sep 2015 B2
9131897 Harada et al. Sep 2015 B2
9155590 Mathur Oct 2015 B2
9162037 Belson et al. Oct 2015 B2
9179972 Olson Nov 2015 B2
9186481 Avitall et al. Nov 2015 B2
9192769 Donofrio et al. Nov 2015 B2
9211405 Mahapatra et al. Dec 2015 B2
9216055 Spence et al. Dec 2015 B2
9233248 Luther et al. Jan 2016 B2
9237926 Nollert et al. Jan 2016 B2
9262252 Kirkpatrick et al. Feb 2016 B2
9277957 Long et al. Mar 2016 B2
9282910 Narayan et al. Mar 2016 B2
9289258 Cohen Mar 2016 B2
9289606 Paul et al. Mar 2016 B2
9295516 Pearson et al. Mar 2016 B2
9301801 Scheib Apr 2016 B2
9375268 Long Jun 2016 B2
9414881 Callas et al. Aug 2016 B2
9468495 Kunis et al. Oct 2016 B2
9474486 Eliason et al. Oct 2016 B2
9474574 Ibrahim et al. Oct 2016 B2
9480525 Lopes et al. Nov 2016 B2
9486272 Bonyak et al. Nov 2016 B2
9486273 Lopes et al. Nov 2016 B2
9492227 Lopes et al. Nov 2016 B2
9492228 Lopes et al. Nov 2016 B2
9517103 Panescu et al. Dec 2016 B2
9526573 Lopes et al. Dec 2016 B2
9532831 Reinders et al. Jan 2017 B2
9539010 Gagner et al. Jan 2017 B2
9554848 Stewart et al. Jan 2017 B2
9554851 Sklar et al. Jan 2017 B2
9700368 Callas et al. Jul 2017 B2
9724170 Mickelsen Aug 2017 B2
9757193 Zarins et al. Sep 2017 B2
9782099 Williams et al. Oct 2017 B2
9795442 Salahieh et al. Oct 2017 B2
9861802 Mickelsen Jan 2018 B2
9913685 Clark et al. Mar 2018 B2
9931487 Quinn et al. Apr 2018 B2
9987081 Bowers et al. Jun 2018 B1
9999465 Long et al. Jun 2018 B2
10016232 Bowers et al. Jul 2018 B1
10117707 Garcia et al. Nov 2018 B2
10130423 Viswanathan et al. Nov 2018 B1
10172673 Viswanathan et al. Jan 2019 B2
10292755 Arena et al. May 2019 B2
10322286 Viswanathan et al. Jun 2019 B2
10433906 Mickelsen Oct 2019 B2
10433908 Viswanathan et al. Oct 2019 B2
10448989 Arena et al. Oct 2019 B2
10507302 Leeflang et al. Dec 2019 B2
10512505 Viswanathan Dec 2019 B2
10512779 Viswanathan et al. Dec 2019 B2
10517672 Long Dec 2019 B2
20010000791 Suorsa et al. May 2001 A1
20010007070 Stewart et al. Jul 2001 A1
20010044624 Seraj et al. Nov 2001 A1
20020052602 Wang et al. May 2002 A1
20020077627 Johnson et al. Jun 2002 A1
20020087169 Brock et al. Jul 2002 A1
20020091384 Hooven et al. Jul 2002 A1
20020095176 Prestel Jul 2002 A1
20020111618 Stewart et al. Aug 2002 A1
20020156526 Hlavka et al. Oct 2002 A1
20020161323 Miller et al. Oct 2002 A1
20020169445 Jain et al. Nov 2002 A1
20020177765 Bowe et al. Nov 2002 A1
20020183638 Swanson Dec 2002 A1
20030014098 Quijano et al. Jan 2003 A1
20030018374 Paulos Jan 2003 A1
20030023287 Edwards et al. Jan 2003 A1
20030028189 Woloszko et al. Feb 2003 A1
20030050637 Maguire et al. Mar 2003 A1
20030114849 Ryan Jun 2003 A1
20030125729 Hooven et al. Jul 2003 A1
20030130598 Manning et al. Jul 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030204161 Ferek-Petric Oct 2003 A1
20030229379 Maynard Dec 2003 A1
20040039382 Kroll et al. Feb 2004 A1
20040049181 Stewart et al. Mar 2004 A1
20040049182 Koblish et al. Mar 2004 A1
20040082859 Schaer Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087939 Eggers et al. May 2004 A1
20040111087 Stern et al. Jun 2004 A1
20040199157 Palanker et al. Oct 2004 A1
20040215139 Cohen Oct 2004 A1
20040231683 Eng et al. Nov 2004 A1
20040236360 Cohn et al. Nov 2004 A1
20040236419 Milo Nov 2004 A1
20040254607 Wittenberger et al. Dec 2004 A1
20040267337 Hayzelden Dec 2004 A1
20050033282 Hooven Feb 2005 A1
20050187545 Hooven et al. Aug 2005 A1
20050222632 Obino Oct 2005 A1
20050251130 Boveja et al. Nov 2005 A1
20050261672 Deem et al. Nov 2005 A1
20050288730 Deem et al. Dec 2005 A1
20060009755 Sra Jan 2006 A1
20060009759 Chrisitian et al. Jan 2006 A1
20060015095 Desinger et al. Jan 2006 A1
20060015165 Bertolero et al. Jan 2006 A1
20060024359 Walker Feb 2006 A1
20060058781 Long Mar 2006 A1
20060111702 Oral et al. May 2006 A1
20060142801 Demarais et al. Jun 2006 A1
20060167448 Kozel Jul 2006 A1
20060217703 Chornenky et al. Sep 2006 A1
20060241734 Marshall et al. Oct 2006 A1
20060264752 Rubinsky et al. Nov 2006 A1
20060270900 Chin et al. Nov 2006 A1
20060287648 Schwartz Dec 2006 A1
20060293730 Rubinsky et al. Dec 2006 A1
20060293731 Rubinsky et al. Dec 2006 A1
20070005053 Dando Jan 2007 A1
20070021744 Creighton Jan 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070066972 Ormsby et al. Mar 2007 A1
20070129721 Phan et al. Jun 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070156135 Rubinsky et al. Jul 2007 A1
20070167740 Grunewald et al. Jul 2007 A1
20070167940 Stevens-Wright Jul 2007 A1
20070173878 Heuser Jul 2007 A1
20070208329 Ward et al. Sep 2007 A1
20070225589 Viswanathan Sep 2007 A1
20070249923 Keenan Oct 2007 A1
20070260223 Scheibe et al. Nov 2007 A1
20070270792 Hennemann et al. Nov 2007 A1
20080009855 Hamou Jan 2008 A1
20080033426 Machell Feb 2008 A1
20080065061 Viswanathan Mar 2008 A1
20080086120 Mirza et al. Apr 2008 A1
20080091195 Sliwa et al. Apr 2008 A1
20080103545 Bolea et al. May 2008 A1
20080132885 Rubinsky et al. Jun 2008 A1
20080161789 Thao et al. Jul 2008 A1
20080172048 Martin et al. Jul 2008 A1
20080200913 Viswanathan Aug 2008 A1
20080208118 Goldman Aug 2008 A1
20080243214 Koblish Oct 2008 A1
20080249518 Warnking et al. Oct 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080300574 Belson et al. Dec 2008 A1
20080300588 Groth et al. Dec 2008 A1
20080319436 Daniel et al. Dec 2008 A1
20090024084 Khosla et al. Jan 2009 A1
20090048591 Ibrahim et al. Feb 2009 A1
20090062788 Long et al. Mar 2009 A1
20090076409 Wu et al. Mar 2009 A1
20090076500 Azure Mar 2009 A1
20090105654 Kurth et al. Apr 2009 A1
20090138009 Viswanathan et al. May 2009 A1
20090149917 Whitehurst et al. Jun 2009 A1
20090163905 Winkler et al. Jun 2009 A1
20090198300 Zhang et al. Aug 2009 A1
20090228003 Sinelnikov Sep 2009 A1
20090240248 Deford et al. Sep 2009 A1
20090275827 Aiken et al. Nov 2009 A1
20090281477 Mikus et al. Nov 2009 A1
20090306651 Schneider Dec 2009 A1
20100004623 Hamilton et al. Jan 2010 A1
20100023004 Francischelli et al. Jan 2010 A1
20100137861 Soroff et al. Jun 2010 A1
20100185140 Kassab et al. Jul 2010 A1
20100185186 Longoria Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100191232 Boveda Jul 2010 A1
20100204619 Rosenberg Aug 2010 A1
20100241185 Mahapatra et al. Sep 2010 A1
20100261994 Davalos et al. Oct 2010 A1
20100274238 Klimovitch Oct 2010 A1
20100280513 Juergen et al. Nov 2010 A1
20100280539 Miyoshi et al. Nov 2010 A1
20100292687 Kauphusman et al. Nov 2010 A1
20100312096 Guttman et al. Dec 2010 A1
20100312300 Ryu et al. Dec 2010 A1
20110028962 Werneth et al. Feb 2011 A1
20110028964 Edwards Feb 2011 A1
20110040199 Hopenfeld Feb 2011 A1
20110098694 Long Apr 2011 A1
20110106221 Neal et al. May 2011 A1
20110130708 Perry et al. Jun 2011 A1
20110144524 Fish et al. Jun 2011 A1
20110144633 Govari Jun 2011 A1
20110160785 Mori et al. Jun 2011 A1
20110190659 Long et al. Aug 2011 A1
20110190727 Edmunds et al. Aug 2011 A1
20110213231 Hall et al. Sep 2011 A1
20110276047 Sklar et al. Nov 2011 A1
20110276075 Fung et al. Nov 2011 A1
20110288544 Verin et al. Nov 2011 A1
20110288547 Morgan et al. Nov 2011 A1
20110313417 De et al. Dec 2011 A1
20120029512 Willard et al. Feb 2012 A1
20120046570 Mllegas et al. Feb 2012 A1
20120053581 Wittkampf et al. Mar 2012 A1
20120059255 Paul et al. Mar 2012 A1
20120071872 Rubinsky et al. Mar 2012 A1
20120078320 Schotzko et al. Mar 2012 A1
20120078343 Fish Mar 2012 A1
20120089089 Swain et al. Apr 2012 A1
20120095459 Callas et al. Apr 2012 A1
20120095461 Herscher et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120158021 Morrill Jun 2012 A1
20120165667 Altmann et al. Jun 2012 A1
20120172859 Condie et al. Jul 2012 A1
20120172867 Ryu et al. Jul 2012 A1
20120197100 Razavi et al. Aug 2012 A1
20120209260 Lambert et al. Aug 2012 A1
20120220998 Long et al. Aug 2012 A1
20120265198 Crow et al. Oct 2012 A1
20120283582 Mahapatra et al. Nov 2012 A1
20120303019 Zhao et al. Nov 2012 A1
20120310052 Mahapatra et al. Dec 2012 A1
20120310230 Willis Dec 2012 A1
20120310237 Swanson Dec 2012 A1
20120316557 Sartor et al. Dec 2012 A1
20130030430 Stewart et al. Jan 2013 A1
20130060247 Sklar et al. Mar 2013 A1
20130060248 Sklar et al. Mar 2013 A1
20130079768 De et al. Mar 2013 A1
20130090651 Smith Apr 2013 A1
20130096655 Moffitt et al. Apr 2013 A1
20130103027 Sklar et al. Apr 2013 A1
20130103064 Arenson et al. Apr 2013 A1
20130131662 Wittkampf May 2013 A1
20130158538 Govari Jun 2013 A1
20130158621 Ding et al. Jun 2013 A1
20130172715 Just et al. Jul 2013 A1
20130172864 Ibrahim et al. Jul 2013 A1
20130172875 Govari et al. Jul 2013 A1
20130184702 Neal et al. Jul 2013 A1
20130218157 Callas et al. Aug 2013 A1
20130226174 Ibrahim et al. Aug 2013 A1
20130237984 Sklar Sep 2013 A1
20130253415 Sano et al. Sep 2013 A1
20130296679 Condie et al. Nov 2013 A1
20130310829 Cohen Nov 2013 A1
20130317385 Sklar et al. Nov 2013 A1
20130331831 Werneth et al. Dec 2013 A1
20130338467 Grasse et al. Dec 2013 A1
20140005664 Govari et al. Jan 2014 A1
20140024911 Harlev et al. Jan 2014 A1
20140039288 Hue-Teh Feb 2014 A1
20140051993 McGee Feb 2014 A1
20140052118 Laske et al. Feb 2014 A1
20140052126 Long et al. Feb 2014 A1
20140052216 Long et al. Feb 2014 A1
20140058377 Deem et al. Feb 2014 A1
20140081113 Cohen et al. Mar 2014 A1
20140100563 Govari et al. Apr 2014 A1
20140107644 Falwell et al. Apr 2014 A1
20140142408 De et al. May 2014 A1
20140148804 Ward et al. May 2014 A1
20140163480 Govari et al. Jun 2014 A1
20140163546 Govari et al. Jun 2014 A1
20140171942 Werneth et al. Jun 2014 A1
20140180035 Anderson Jun 2014 A1
20140187916 Clark et al. Jul 2014 A1
20140194716 Diep et al. Jul 2014 A1
20140194867 Fish et al. Jul 2014 A1
20140200567 Cox et al. Jul 2014 A1
20140235986 Harlev et al. Aug 2014 A1
20140235988 Ghosh Aug 2014 A1
20140235989 Wodlinger et al. Aug 2014 A1
20140243851 Cohen et al. Aug 2014 A1
20140253140 Gilbert Sep 2014 A1
20140276712 Mallin et al. Sep 2014 A1
20140276760 Bonyak et al. Sep 2014 A1
20140276782 Paskar Sep 2014 A1
20140276791 Ku et al. Sep 2014 A1
20140288556 Ibrahim et al. Sep 2014 A1
20140303721 Fung et al. Oct 2014 A1
20140343549 Spear et al. Nov 2014 A1
20140364845 Rashidi Dec 2014 A1
20140371613 Narayan et al. Dec 2014 A1
20150005767 Werneth et al. Jan 2015 A1
20150011995 Avitall et al. Jan 2015 A1
20150066108 Shi et al. Mar 2015 A1
20150119674 Fischell et al. Apr 2015 A1
20150126840 Thakur et al. May 2015 A1
20150133914 Koblish May 2015 A1
20150138977 Dacosta May 2015 A1
20150141978 Subramaniam et al. May 2015 A1
20150142041 Kendale et al. May 2015 A1
20150148796 Bencini May 2015 A1
20150150472 Harlev et al. Jun 2015 A1
20150157402 Kunis et al. Jun 2015 A1
20150157412 Wallace et al. Jun 2015 A1
20150164584 Davalos et al. Jun 2015 A1
20150173824 Davalos et al. Jun 2015 A1
20150173828 Avitall Jun 2015 A1
20150174404 Rousso et al. Jun 2015 A1
20150182740 Mickelsen Jul 2015 A1
20150196217 Harlev et al. Jul 2015 A1
20150223726 Harlev et al. Aug 2015 A1
20150230699 Berul et al. Aug 2015 A1
20150258344 Tandri et al. Sep 2015 A1
20150265342 Long et al. Sep 2015 A1
20150265344 Aktas et al. Sep 2015 A1
20150272656 Chen Oct 2015 A1
20150272664 Cohen Oct 2015 A9
20150272667 Govari et al. Oct 2015 A1
20150282729 Harlev et al. Oct 2015 A1
20150289923 Davalos et al. Oct 2015 A1
20150304879 Dacosta Oct 2015 A1
20150320481 Cosman et al. Nov 2015 A1
20150321021 Tandri et al. Nov 2015 A1
20150327944 Neal et al. Nov 2015 A1
20150342532 Basu et al. Dec 2015 A1
20150343212 Rousso et al. Dec 2015 A1
20150351836 Prutchi Dec 2015 A1
20150359583 Swanson Dec 2015 A1
20160000500 Salahieh et al. Jan 2016 A1
20160008061 Fung et al. Jan 2016 A1
20160008065 Gliner et al. Jan 2016 A1
20160029960 Toth et al. Feb 2016 A1
20160038772 Thapliyal et al. Feb 2016 A1
20160051204 Harlev et al. Feb 2016 A1
20160051324 Stewart et al. Feb 2016 A1
20160058493 Neal et al. Mar 2016 A1
20160058506 Spence et al. Mar 2016 A1
20160066993 Avitall et al. Mar 2016 A1
20160074679 Thapliyal et al. Mar 2016 A1
20160095531 Narayan et al. Apr 2016 A1
20160095642 Deno et al. Apr 2016 A1
20160095653 Lambert et al. Apr 2016 A1
20160100797 Mahapatra et al. Apr 2016 A1
20160100884 Fay et al. Apr 2016 A1
20160106498 Highsmith et al. Apr 2016 A1
20160106500 Olson Apr 2016 A1
20160113709 Maor Apr 2016 A1
20160113712 Cheung et al. Apr 2016 A1
20160120564 Kirkpatrick et al. May 2016 A1
20160128770 Afonso et al. May 2016 A1
20160166167 Narayan et al. Jun 2016 A1
20160166310 Stewart et al. Jun 2016 A1
20160166311 Long et al. Jun 2016 A1
20160174865 Stewart et al. Jun 2016 A1
20160183877 Williams et al. Jun 2016 A1
20160184003 Srimathveeravalli et al. Jun 2016 A1
20160184004 Hull et al. Jun 2016 A1
20160213282 Leo et al. Jul 2016 A1
20160220307 Miller et al. Aug 2016 A1
20160235470 Callas et al. Aug 2016 A1
20160287314 Arena et al. Oct 2016 A1
20160296269 Rubinsky Oct 2016 A1
20160310211 Long Oct 2016 A1
20160324564 Gerlach et al. Nov 2016 A1
20160324573 Mickelson et al. Nov 2016 A1
20160331441 Konings Nov 2016 A1
20160331459 Townley et al. Nov 2016 A1
20160354142 Pearson et al. Dec 2016 A1
20160361109 Weaver et al. Dec 2016 A1
20170001016 De Ridder Jan 2017 A1
20170035499 Stewart Feb 2017 A1
20170042449 Deno et al. Feb 2017 A1
20170042615 Salahieh et al. Feb 2017 A1
20170056648 Syed et al. Mar 2017 A1
20170065330 Mickelsen et al. Mar 2017 A1
20170065339 Mickelsen Mar 2017 A1
20170065340 Long Mar 2017 A1
20170065343 Mickelsen Mar 2017 A1
20170071543 Basu et al. Mar 2017 A1
20170095291 Harrington et al. Apr 2017 A1
20170105793 Cao et al. Apr 2017 A1
20170120048 He et al. May 2017 A1
20170146584 Daw et al. May 2017 A1
20170151029 Mickelsen Jun 2017 A1
20170172654 Wittkampf et al. Jun 2017 A1
20170181795 Debruyne Jun 2017 A1
20170189097 Mswanathan et al. Jul 2017 A1
20170215953 Long et al. Aug 2017 A1
20170245928 Xiao et al. Aug 2017 A1
20170246455 Athos et al. Aug 2017 A1
20170312024 Harlev et al. Nov 2017 A1
20170312025 Harlev et al. Nov 2017 A1
20170312027 Harlev et al. Nov 2017 A1
20180001056 Leeflang et al. Jan 2018 A1
20180042674 Mickelsen Feb 2018 A1
20180042675 Long Feb 2018 A1
20180043153 Viswanathan et al. Feb 2018 A1
20180064488 Long et al. Mar 2018 A1
20180085160 Viswanathan et al. Mar 2018 A1
20180093088 Mickelsen Apr 2018 A1
20180133460 Townley et al. May 2018 A1
20180168511 Hall et al. Jun 2018 A1
20180184982 Basu et al. Jul 2018 A1
20180193082 Rubinsky Jul 2018 A1
20180193090 De et al. Jul 2018 A1
20180200497 Mickelsen Jul 2018 A1
20180289417 Schweitzer et al. Oct 2018 A1
20180303488 Hill Oct 2018 A1
20180311497 Viswanathan et al. Nov 2018 A1
20180344393 Gruba et al. Dec 2018 A1
20180360534 Teplitsky et al. Dec 2018 A1
20190038171 Howard Feb 2019 A1
20190046791 Ebbers et al. Feb 2019 A1
20190069950 Viswanathan et al. Mar 2019 A1
20190125439 Rohl et al. May 2019 A1
20190151015 Viswanathan et al. May 2019 A1
20190183378 Mosesov et al. Jun 2019 A1
20190209238 Jimenez Jul 2019 A1
20190223938 Arena et al. Jul 2019 A1
20190223950 Gelbart et al. Jul 2019 A1
20190231421 Viswanathan et al. Aug 2019 A1
20190233809 Neal et al. Aug 2019 A1
20190256839 Neal et al. Aug 2019 A1
20190269912 Viswanathan et al. Sep 2019 A1
20190328445 Sano et al. Oct 2019 A1
20190336198 Viswanathan et al. Nov 2019 A1
20190336207 Viswanathan Nov 2019 A1
20190336757 Rodriguez et al. Nov 2019 A1
20190376055 Davalos et al. Dec 2019 A1
20200107879 Stewart et al. Apr 2020 A1
20210031020 Mickelsen Feb 2021 A1
20220000548 Mickelsen Jan 2022 A1
Foreign Referenced Citations (101)
Number Date Country
1042990 Oct 2000 EP
1125549 Aug 2001 EP
0797956 Jun 2003 EP
1340469 Sep 2003 EP
1127552 Jun 2006 EP
1803411 Jul 2007 EP
1009303 Jun 2009 EP
2213729 Aug 2010 EP
2382935 Nov 2011 EP
2425871 Mar 2012 EP
2532320 Dec 2012 EP
2587275 May 2013 EP
2663227 Nov 2013 EP
1909678 Jan 2014 EP
2217165 Mar 2014 EP
2376193 Mar 2014 EP
2708181 Mar 2014 EP
2777579 Sep 2014 EP
2777585 Sep 2014 EP
2934307 Oct 2015 EP
3056242 Aug 2016 EP
3111871 Jan 2017 EP
3151773 Apr 2018 EP
06-507797 Sep 1994 JP
10-510745 Oct 1998 JP
2000-508196 Jul 2000 JP
2005-003394 Jan 2005 JP
2005-516666 Jun 2005 JP
2006-506184 Feb 2006 JP
2007-325935 Dec 2007 JP
2008-538997 Nov 2008 JP
2009-500129 Jan 2009 JP
2011-509158 Mar 2011 JP
2012-050538 Mar 2012 JP
2016-515869 Jun 2016 JP
2019-503773 Feb 2019 JP
2019-522515 Aug 2019 JP
9207622 May 1992 WO
9221278 Dec 1992 WO
9221285 Dec 1992 WO
9407413 Apr 1994 WO
9724073 Jul 1997 WO
9725917 Jul 1997 WO
9737719 Oct 1997 WO
9904851 Feb 1999 WO
9922659 May 1999 WO
9956650 Nov 1999 WO
9959486 Nov 1999 WO
0256782 Jul 2002 WO
0353289 Jul 2003 WO
0365916 Aug 2003 WO
2004045442 Jun 2004 WO
2004086994 Oct 2004 WO
2005046487 May 2005 WO
2006115902 Nov 2006 WO
2007006055 Jan 2007 WO
2007079438 Jul 2007 WO
2009082710 Jul 2009 WO
2009089343 Jul 2009 WO
2009137800 Nov 2009 WO
2010014480 Feb 2010 WO
2011028310 Mar 2011 WO
2011154805 Dec 2011 WO
2012051433 Apr 2012 WO
2012097067 Jul 2012 WO
2012153928 Nov 2012 WO
2012156944 Nov 2012 WO
2013019385 Feb 2013 WO
2014025394 Feb 2014 WO
2014031800 Feb 2014 WO
2014036439 Mar 2014 WO
2014100579 Jun 2014 WO
2014160832 Oct 2014 WO
2015066322 May 2015 WO
2015099786 Jul 2015 WO
2015103530 Jul 2015 WO
2015103574 Jul 2015 WO
2015130824 Sep 2015 WO
2015140741 Sep 2015 WO
2015143327 Sep 2015 WO
2015171921 Nov 2015 WO
2015175944 Nov 2015 WO
2015192018 Dec 2015 WO
2015192027 Dec 2015 WO
2016059027 Apr 2016 WO
2016060983 Apr 2016 WO
2016081650 May 2016 WO
2016090175 Jun 2016 WO
2017093926 Jun 2017 WO
2017119934 Jul 2017 WO
2017120169 Jul 2017 WO
2017192477 Nov 2017 WO
2017192495 Nov 2017 WO
2017218734 Dec 2017 WO
2018005511 Jan 2018 WO
2018191149 Oct 2018 WO
2018200800 Nov 2018 WO
2019118436 Jun 2019 WO
2019133606 Jul 2019 WO
2019234133 Dec 2019 WO
WO-2020051241 Mar 2020 WO
Non-Patent Literature Citations (12)
Entry
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/052478, mailed on Mar. 30, 2022, 13 pages.
Du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013).
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages.
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007].
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016).
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014).
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014).
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014).
Van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015).
Van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014).
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011).
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012).
Related Publications (1)
Number Date Country
20220096151 A1 Mar 2022 US
Provisional Applications (1)
Number Date Country
63085452 Sep 2020 US